Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An investigator-initiated trials phase Ib/II trial of CT-0596 for primary plasma cell leukemia (pPCL)

Next Previous
Trial Profile

An investigator-initiated trials phase Ib/II trial of CT-0596 for primary plasma cell leukemia (pPCL)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CT 0596 (Primary)
  • Indications Leukaemia; Plasma cell leukaemia
  • Focus Therapeutic Use

Most Recent Events

  • 09 Jan 2026 New trial record
  • 28 Dec 2025 According to a CARsgen media release, company has submitted two separate Investigational New Drug (IND) applications to the National Medical Products Administration (NMPA) for its allogeneic BCMA-targeted CAR-T cell therapy product, CT0596, for treatment of primary plasma cell leukemia (pPCL).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top